# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

> **NCT07234942** · PHASE1 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 50 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** RO7812653
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07234942
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2028-04-19
- **Final completion:** 2030-03-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07234942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07234942, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT07234942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*